The estimated Net Worth of Carl Dockery is at least $2.34 Million dollars as of 27 February 2017. Mr. Dockery owns over 416,667 units of Aytu BioPharma Inc stock worth over $2,101,623 and over the last 9 years he sold AYTU stock worth over $0. In addition, he makes $239,850 as Independent Director at Aytu BioPharma Inc.
Carl has made over 2 trades of the Aytu BioPharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 416,667 units of AYTU stock worth $312,500 on 27 February 2017.
The largest trade he's ever made was buying 5,000,000 units of Aytu BioPharma Inc stock on 6 May 2016 worth over $2,000,000. On average, Carl trades about 492,424 units every 27 days since 2016. As of 27 February 2017 he still owns at least 837,300 units of Aytu BioPharma Inc stock.
You can see the complete history of Mr. Dockery stock trades at the bottom of the page.
Carl C. Dockery serves as Independent Director of the Company. Mr. Dockery joined our Board of Directors in April 2016. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery’s career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd’s and the London Underwriting Centre brokering various types of reinsurance placements. Mr. Dockery serves as a director of CytoDyn Inc. (OTCQB: CYDY), a biotechnology company. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities. Mr. Dockery’s financial expertise and experience, as well as his experience as a director of a publicly traded biopharmaceutical company, led to the conclusion that he should serve as a director of our Company in light of our business and structure.
As the Independent Director of Aytu BioPharma Inc, the total compensation of Carl Dockery at Aytu BioPharma Inc is $239,850. There are 5 executives at Aytu BioPharma Inc getting paid more, with Joshua Disbrow having the highest compensation of $1,043,700.
Carl Dockery is 57, he's been the Independent Director of Aytu BioPharma Inc since 2016. There are 3 older and 7 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.
Carl's mailing address filed with the SEC is C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.
Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery, and Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
Aytu BioPharma Inc executives and other stock owners filed with the SEC include: